US FDA submissions pit Novartis and Kite head-to-head in CAR race 04-Apr-2017 By Dan Stanton Novartis and Kite Pharma have both submitted autologous leukemia candidates for review, paving the road for the first available chimeric antigen receptor (CAR) T cell therapy.
Draper looks to ultrasound and geometry to reduce CAR-T manufacturing costs 07-Feb-2017 By Dani Bancroft The Charles Stark Draper Lab has developed two microfluidic prototypes to help make the manufacturing of cell therapies cheaper and more efficient.
Juno buys cell sequencing firm; set to license tech to CAR-T partner Celgene 13-Jan-2016 By Dan Stanton T-cell receptor specialist Juno Therapeutics has added a next-generation single cell sequencing platform through the $125m acquisition of AbVitro.
Cellectis' off-the-shelf CAR T-Cells treat 11-month old with leukaemia 10-Nov-2015 By Dan Stanton An ‘off-the-shelf’ CAR (chimeric-antigen receptor) T-Cell therapy from Cellectis has shown to have successfully treated a baby girl with leukaemia.
$1bn T-cell immune-oncology JV for Celgene and Juno 08-Jul-2015 By Fiona BARRY US biopharmas Celgene and Juno are entering a $1bn, 10-year immunotherapy partnership.